ONCLIVE NEWS NETWORK: ON LOCATION WILL BE LIVE AT ESMO THIS WEEK - STAY TUNED FOR MORE INFORMATION!

Dr. Caligiuri on the Anti-KIR Antibody IPH2101

Michael A. Caligiuri, MD
Published: Thursday, Dec 19, 2013

Michael A. Caligiuri, MD, CEO, The James Cancer Hospital Solove Research Institute, director, Comprehensive Cancer Center, Ohio State University, discusses the anti-KIR antibody IPH2101 in myeloma and leukemia.

Caligiuri says the antibody removes the “stop sign” from the natural killer (NK) immune cell, allowing the NK cell to attack the tumor. The natural killer cell has a lot of activity against multiple myeloma and acute myeloid leukemia.

The anti-KIR antibody has shown promise in a phase I study and has shown evidence of anti-tumor activity. Caligiuri says that this agent, which was initially developed by Innate Pharma and is being further developed by Bristol-Myers Squibb, is moving ahead in a number of different diseases.

Michael A. Caligiuri, MD, CEO, The James Cancer Hospital Solove Research Institute, director, Comprehensive Cancer Center, Ohio State University, discusses the anti-KIR antibody IPH2101 in myeloma and leukemia.

Caligiuri says the antibody removes the “stop sign” from the natural killer (NK) immune cell, allowing the NK cell to attack the tumor. The natural killer cell has a lot of activity against multiple myeloma and acute myeloid leukemia.

The anti-KIR antibody has shown promise in a phase I study and has shown evidence of anti-tumor activity. Caligiuri says that this agent, which was initially developed by Innate Pharma and is being further developed by Bristol-Myers Squibb, is moving ahead in a number of different diseases.




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x